EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Real-World Impact of Mepolizumab in COPD in a US Commercial and Medicare Claims Database

Reynold A Panettieri iD, Rosirene Paczkowski, Hannah Mei, Emmeline Burrows, Guillaume Germain, Sunay Shah, Jacob Klimek, Sophie Ma, Sarah Cooper, François Laliberté, Antonio Anzueto

International Journal of Chronic Obstructive Pulmonary Disease · 2026

DOI: 10.2147/copd.s623966 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2026. Verfasst von Reynold A Panettieri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Institute for Translational Medicine and Science, The State University of New Jersey, New Brunswick, NJ, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Pulmonary Disease, Chronic Obstructive, Medicare. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPulmonary Disease, Chronic ObstructiveMedicareHumansUnited StatesRetrospective StudiesFemaleAgedDatabases, FactualMaleTreatment OutcomeMiddle AgedLongitudinal StudiesDisease ProgressionTime FactorsHospitalization

Stichwörter der Autor:innen

Medicareexacerbationshealthcare resource utilizationhospitalizationsmepolizumabreal-world claims database analysis

Substanzen

Antibodies, Monoclonal, Humanizedmepolizumab

Autor:innen und Institutionen

  • Rutgers Institute for Translational Medicine and Science, The State University of New Jersey, New Brunswick, NJ, USA.
  • Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Global Real-World Evidence and Health Outcomes Research, GSK, Collegeville, PA, USA.
  • US Medical Affairs, R&D Global Medical, GSK, Durham, NC, USA.
  • Groupe d'analyse SRI, Montréal, QC, Canada.
  • US Medical Affairs, GSK, Collegeville, PA, USA.

ORCID-Profile: Reynold A Panettieri

Zitieren

APA

Panettieri, R. A., Paczkowski, R., Mei, H., Burrows, E., Germain, G., Shah, S., Klimek, J., Ma, S., Cooper, S., Laliberté, F., & Anzueto, A. (2026). Real-World Impact of Mepolizumab in COPD in a US Commercial and Medicare Claims Database. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s623966

Vancouver

Panettieri RA, Paczkowski R, Mei H, Burrows E, Germain G, Shah S, et al. Real-World Impact of Mepolizumab in COPD in a US Commercial and Medicare Claims Database. International Journal of Chronic Obstructive Pulmonary Disease. 2026. doi:10.2147/copd.s623966

BibTeX
@article{Panettieri2026,
  author = {Panettieri, Reynold A and Paczkowski, Rosirene and Mei, Hannah and Burrows, Emmeline and Germain, Guillaume and Shah, Sunay and Klimek, Jacob and Ma, Sophie and Cooper, Sarah and Laliberté, François and Anzueto, Antonio},
  title = {Real-World Impact of Mepolizumab in COPD in a US Commercial and Medicare Claims Database},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2026},
  doi = {10.2147/copd.s623966}
}
Kostenlos starten →